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Abstract 
Background:To determine the efficacy of 
intraumbilical oxytocin in reducing duration of third 
stage of labor, compared to routine active 
management of third stage of labor(AMTSL). 
Methods: In this randomized controlled trial one 
hundred parturient women were divided in two 
groups consisting of 50 each. Active management of 
third stage was done in both the groups. The study 
group in addition to active management, received 
oxytocin 10 international units( IU) diluted in 10ml 
normal saline through the umbilical vein and  
control group received  equal volume of normal 
saline as placebo .The mean time taken for the 
completion of third stage was calculated for both 
groups in terms of minutes. The mean time “t” 
between the two groups was compared using 
Independent sample- t test. P value<0.05 was taken 
significant. 
Results: The mean duration of third stage of labor 
was 4.38±0.88 minutes in the study group, compared 
to 5.12±1.32 minutes  in the control group which was 
significant statistically p=0.001. There was no 
incidence of retained placenta and none of placenta 
remain undelivered beyond 15 minutes in both 
groups.  
Conclusion:  Intraumbilical oxytocin when given 
along with active management significantly reduces 
the mean duration of third stage of labour, compared 
to active management alone.  
Key Words: Oxytocin, Third stage of Labour, 
Intraumbilical uterotonics. 
 
Introduction 
Actively managed third stage is known to reduce the 
incidence of retained placenta and life threatening 
blood loss. Recently studies to evaluate the efficacy of 
uterotonics like oxytocin or misoprostol administered 
through the umbilical vein using pipingas technique in 
reducing the duration of third stage of labour, 
incidence of retained placenta, and associated blood 
loss, show controversial results.Third stage of labour is 
an important event occurring during normal vaginal 
delivery. Third stage of labour commences with the 
delivery of the baby till delivery of placenta and 
membranes. The uterus contracts and retracts even 
after delivery of the baby, which facilitates the 
separation of placenta, and occludes the blood flow to 
the placental site by compression due to criss cross 
arrangement of smooth musculature. Hence a 
prolonged third stage and retained placenta can lead 
to major obstetric haemorrhage. An attempt to prevent 
such catastrophies  has lead to development of third 
stage of labour. If managed expectantly third stage of 
labour can last up to one hour. But when actively 
managed it lasts from 5 to 15 minutes. Risk of 
postpartum haemorrhage (PPH) increases significantly 
when duration of third stage is 20 minutes or more.1 
AMTSL, includes the use of uterotonics (Oxytocin), 
early clamping of umbilical cord and controlled cord 
traction(CCT) for delivery of placenta using the Brandt 
Andrews method and uterine massage .AMTSL can 
saves the woman from life threatening blood loss 
around 1000ml.2  Postpartum haemoglobin was higher, 
and duration of third stage was shorter (p=0.001) in 
actively managed group.3 Controlled cord traction 
decreases the risk of manual removal of placenta and 
PPH.4,5 Use of oxytocin in AMTSL and CCT reduce 
risk of PPH by 66%. 6 
About 83.3% maternal deaths in Pakistan are caused 
by serious postpartum bleeding7. Most women are 
anaemic due to malnutrition, repeated child births and 
a general trend in low socio economic group to seek 
traditional attendants, who have no knowledge about 
timely use of uterotonics and their 
importance.AMTSL,with oxytocin as uterotonic  is a 
good strategy for preventing PPH in low resource 
countries. However due to it’s heat instability and 
requirement of a trained person,misopprostol can be 
used.8 
Natural Oxytocin is a peptide hormone released from 
posterior pituitary. Synthetic Preparations have wide 
spread use. Oxytocin is the preferred uterotonic in 
AMTSL when compared to,ergometrine,due its serious 
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cardiovascular side effects9.Another study found 
oxytocin more effective in preventing uterine 
atony,than misoprostol.10 
 Recent trials have compared the efficacy of different 
uterotonics injected through the umbilical vein using 
piping as technique. Our local study using 
intraumbilical oxytocin showed significant reduction 
in duration of the third stage of labour. This study 
used combination of oxytocin and Ergometrine as 
active management. The mean time duration was 
2.59±0.52 minutes in study group, and 7.56 
minutes±3.9 in control group, which was statistically 
significant (p=0.001, 95% C1 4.80-5.46).11 
 Accoding to recent  guidelines on PPH, ergometerine 
+ oxytocin versus oxytocin 5 and 10 international 
units(IU), alone have similar efficacy in prevention of 
postpartum hemorrhage. The prophylactic of 
ergometrine needs to be weighed against its adverse 
effects. Ergometrine itself causes strong uterine 
contractions and facilitates delivery of placenta, hence 
appears to be a confounding factor. Therefore in our 
study diluted oxytocin 10 IU was used both for 
intravenous and intraumbilical routes .The procedure 
is simple, inexpensive and without serious maternal or 
fetal side effects.  
Patients and Methods  
One hundred parturient women were included in this 
study conducted at Pakistan Railways hospital 
between  Dec 2012,till May 2013 . Fifty patients were 
assigned randomly to each group after fulfilling the 
inclusion criteria. Low risk, singleton, term ( 37-40 
completed weeks of gestation) women, with cephalic 
presentation of the baby in spontaneous labour, were 
enrolled. All high risk cases, i.e pre eclampsia 
hypertension, multiple pregnancies, preterm or post 
dates, previous cesarean section, diabetes and fetal 
macrosomia, severe anaemia, other medical disorders, 
and contraindication for vaginal delivery were 
excluded. All patients were booked (least six antenatal 
visits) Parity of the patients ranged from 0-5 and Age 
from  21-35years.A time duration of greater than 15 
minutes was considered a prolonged third stage. 
Study was conducted by making two equal groups 50 
each. Allocation to either group was random using 
lottery method. Patients with non reassuring 
cardiotocograph( CTG )or poor progress of labour 
were excluded.When cervical dilatation was 7-8cm, 
labour room staff was alerted to prepare delivery 
trolley and Intraumbilical injections. Oxytocin solution 
(10 IU+ normal saline 10ml) labelled as syringe A, or 
equal volume of placebo labelled as syringe B .Active 
management of third stage was done in both the 
groups, which included  Intravenous oxytocin (10 IU)  
slowly  at the delivery of anterior shoulder of the baby. 
Umbilical cord was clamped as soon as baby was 
delivered. Intraumbilical injection was given after 
delivery of the baby, through syringe about 2cm away 
from introitus, over 20 to 30 seconds and solution was 
milked towards cord insertion.  In this way the study 
group A, in addition to active management, received 
oxytocin solution through the umbilical vein, and 
control Group B received active management and 
equal volume of placebo. Delivery of placenta was 
facilitated by Brandt Andrew method of controlled 
cord traction both groups, when signs of placental 
separation were observed. The time taken for the 
completion of third stage was calculated in terms of 
minutes. The mean time “t” between the two groups 
was compared using Independent sample- t test. A  p 
value<0.05 was taken significant.  
Results 
Parity ranged from 0 to 5. Majority were multiparous 
with only 21 primigravidas (Table 1). Mean parity 
being 2.9±1.54 in study group and 2.62±1.25 in control 
group (Table 2). Age ranged from 21 to 35years, with 
60 women  between 21-29years.Mean age in study and 
contol groups were 26.56±0.84,26.66±0.82 respectively 
(Table 3). The mean duration of third stage of labor 
was 4.38±0.88 minutes in the study group ,compared 
to 5.12±1.32 minutes in the control group  which was 
significant statistically p=0.001 (Table 4). 
Table 1. Parity of patients and their percentage 
 Parity  Frequency Percent 
 
Primigravida 21 21.0 
1 26 26.0 
2 27 27.0 
3 14 14.0 
4 6 6.0 
5 6 6.0 
Total 100 100.0 
There was no incidence of retained placenta 0% and 
none of the placenta remain undelivered beyond 15 
minutes (our specified time limit) in either of the 
groups.  
 
Table 2. Duration of third stage of labour 
Intraumbilic
al oxytocin  
VS control 
 No  Mean + 
SD 
Std.Err
or 
Mean 
Mean 
duration of 
3rd stage of 
labour  
(A)Study 50 4.38+0.884 0.12451 
(B)Control  50 5.126+1.32 0.18713 
p-value = 0.001 
Hence third stage was not considered prolonged in 
both groups (15 ≥min), although it was shorter with 
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the addition of intraumbilical oxytocin when given 
along with the active management of third stage of 
labor. 
 
Table  3. Age of patients and their percentage 
 Age of patients in years Frequency Percent 
 
21-24yrs         29 29.0 
25-29yrs 31 31.0 
30-35yrs 40 40.0 
Total 100 100.0 
 
Table 4. Age, duration of third stage, parity 
 A study, B control Parity 
 of patients 
Age  
in yrs 
Time  
In 
minutes 
A         Mean 
             N 
           Std.deviation 
     2.9000 
     50 
     1.5419 
  26.56 
   50 
   0.8429 
 4.3880 
  50 
 0.8804 
B        Mean 
          N 
          Std deviation 
    2.6200 
    50 
    1.2599 
 26.66 
  50 
 0.8171 
5.1262 
 50 
1.3232 
Total    Mean 
              N 
             Std  
   2.7600 
  100 
   1.4079 
 26.61 
 100 
0.8274 
 4.7571 
 100 
 1.17808 
 
Discussion 
According to a study rate of AMTSL was 57% in Irani 
population.Oxytocin was used by 94% ,71% applied 
early clamping of umbilical cord and 65% used 
controlled cord traction.12 Another study showed 
adequately performed AMTSL was only 48% in 
vaginal delieveries.13There are variations in relation to 
choice of uterotonic, optimal dosing and time of 
administration.A study comparing  intraumbilical 
oxytocin,intravenous carbetocin and sublingual 
misoprostol found that carbetocin  was more 
effective(16.6±3.76 min) than Intraumbilical oxytocin 
(18.28±3.34 min) and misoprostol.(23.00±3.38min).14 
Habek D et al compared oxytocin, prostaglandins and 
ergot via umbilical route. The success rates in reducing 
duration of third stage were, 76.9%, 85.7%and 64.2% 
respectively.15While  some  studies  showed that  
misoprostol  was more effective than oxytocin solution 
when given through umbilical route.16 Gungorduk et 
al  found significant reduction in mean time of third 
stage in oxytocin group as compared to 
placebo(4.5±1.6min compared to 7.9±3.4 min 
p<0.001).17 Studies found the Intraumbilical 
intervention effective and safe.18,19  According to a  
randomized controlled trial a significant reduction in 
the rate of manual removal of placenta, uterine atony 
and need for additional uterotonics observed in  the 
Intraumbilical oxytocin group compared to 
controls.20.Contrary to this, a systemic review found no 
role of oxytocin once a diagnosis a retained placenta 
was made. 21  
The strength of present study includes its design. In 
present study 10 IU oxytocin was used to avoid any 
harmful effect. Active management of third stage was 
done in both groups .In order to minimize the bias we 
provided the doctors conducting deliveries with equal 
volume of normal saline as placebo. One of the 
limitations of our study is that all term pregnancies 
(≥37-40 weeks of gestation) were included, while the 
risk of retained placenta and delayed third stage is 
more commonly associated with preterm deliveries. 
Secondly the age limit in our study was up to 35 years. 
Once again older maternal age is correlated with 
prolonged third stage and risk of PPH.We excluded 
the high risk cases e.g previous scar,multiple 
pregnancies, prolonged second stage and instrumental 
deliveries , medical disorders such as preeclampsia, 
severe anaemia, diabetes etc. So any benefit to high 
risk group has not be studied. Since there was no 
incidence of retained placenta ,and none of placenta 
delivered beyond 15 minutes so active management of 
third stage still proved to be effective, and at present is 
the gold standard. 
  Use of intraumbilical route   is an additional 
intervention ,which  may be attempted by a skilled 
person if placental separation has not occurred till 15 
minutes, before attempting manual removal of 
placenta and in patients who are at very high risk of 
retained placenta and prolong third stage. This will 
not only reduce the third stage duration, but saves  the 
patient from anaesthesia hazards , risks of manual 
removal of placenta, blood transfusions, and cost of 
prolonged  hospital stay. 
 
Conclusion 
1.In a dedicated maternity unit , active management 
with timely use of uterotonic in optimal dose and 
route of administration can significantly reduce  span 
of third stage . 
2.Prophylactic use of intraumbilical oxytocin 
alongwith active management can cause a significant 
reduction in the mean duration of third stage of labor. 
However use of intraumbilical route   is an additional 
intervention ,which  may be attempted by a skilled 
person if placental separation has not occurred till 15 
minutes, before attempting manual removal of 
placenta and in patients who are at very high risk of 
retained placenta and prolong third stage. This will 
not only reduce the third stage duration, but saves  the 
patient from anaesthesia hazards , risks of manual 
removal of placenta, blood transfusions, and cost of 
prolonged  hospital stay. 
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